Publication date: Nov 07, 2019
As part of this joint research, Fujitsu Laboratories Ltd. has successfully developed and verified AI technology to improve the efficiency of treatment planning in cancer genomic medicine, demonstrating its effectiveness through verification experiments at the Institute of Medical Science at the University of Tokyo.
Verification trial experiments using this technology have allowed the Department of Hematology and Oncology at the Institute of Medical Science, the University of Tokyo to reduce the amount of work required to determine a treatment plan for acute myeloid leukemia by more than half, delivering improved efficiency.
To address these challenges, Fujitsu Laboratories and the Institute of Medical Science at the University of Tokyo’s launched a joint AI research project beginning in April 2018 to improve the efficiency and sophistication of the work of physicians specializing in cancer genomics, subsequently conducting a verification trial for the technology.
This is accomplished by integrating Fujitsu’s AI technology for language processing, which identifies terms and phrases used in research papers from context, as well as insight of information needed to discuss treatment policies identified by the Institute of Medical Science at the University of Tokyo.
Verification Trial Details With the newly developed technology, 2. 4 million elements of relationships from 860,000 medical papers are automatically extracted as knowledge to construct a knowledge graph database for cancer genomic medicine.
In this study, the time required for 4 physicians specializing in hematological malignancies at the Institute of Medical Science at the University of Tokyo to search and examine papers using the technology based on past cases of acute myeloid leukemia is measured, and the efficiency of examination work with and without the newly developed technology is evaluated.
|disease||DOID||acute myeloid leukemia|
|pathway||BSID||Acute myeloid leukemia|
- Microsoft Using AI to Accelerate Cancer Precision Medicine
- Applications of Bioinformatics in Cancer.
- Dr Per Sikora – Precision Medicine in Sweden, challenges and opportunities
- The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
- Factors associated with oncologist discussions of the costs of genomic testing and related treatments.